Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops may offer a new way to read without glasses — a trial puts them to the test

NCT ID NCT07723716

Symptom relief Sponsor: Taejoon Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This phase 3 trial tests whether CTO0307, a pilocarpine eye drop, can improve near vision in adults aged 40 to 64 with presbyopia — the age-related difficulty seeing up close. Participants receive either the active drop or a placebo for four weeks. The main question is whether more people in the treatment group gain at least three lines on a near-vision chart three hours after each dose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pilocarpine eye drops
What this could lead to
If effective, CTO0307 could offer a non-surgical option to temporarily improve near vision in people with presbyopia.
What could go wrong
This is an early-phase trial with a small number of participants. The effect may be modest or temporary, and eye drops can cause side effects like blurred vision or eye irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

167 people

The number who actually took part.

Started

Feb 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women aged ≥40 years and \<65 years. 2. Patients who meet all of the following visual acuity assessment criteria: ① DCNVA between 20/100 and 20/40 (Snellen equivalent). ② CDVA of 20/25 or better (Snellen equivalent). 3. Patients who are capable of performing all study procedures, including questionnaires and examinations, and willing to cooperate with the investigator's instructions. 4. Patients who voluntarily provided written informed consent, or whose legally authorized representative provided written informed consent, to participate in this clinical trial. Exclusion Criteria: 1. Patients with a history of ophthalmic surgery that may affect the absorption, distribution, or excretion of the investigational product, including cataract surgery, phakic intraocular lens (IOL) surgery, corneal inlay surgery, radial keratotomy (RK), or other intraocular surgeries. 2. Patients with a history of LASIK, LASEK, or PRK (Photorefractive Keratectomy) within one year prior to screening. 3. Patients with a history of hypersensitivity to the components of the investigational product or other cholinergic agonist drugs. 4. Patients with the following conditions known to require cautious administration of the investigational product components: * Bronchial asthma, heart failure, Parkinson's disease. * Gastrointestinal (GI) stenosis (e.g., intestinal obstruction), duodenal ulcer, GI spasms, or clinically significant defecation disorders due to constipation. * Urinary tract obstruction due to urinary tract disorders. 5. Patients who have received at least one dose of another investigational product within 30 days prior to participation in this clinical trial. 6. Patients deemed inappropriate by the investigator due to other diseases or conditions that may affect the evaluation of the efficacy or safety of the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Presbyopia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Presbyopia

Contacts and locations

Locations

  • Kangbook Samsung Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.